Micropapillary ductal carcinoma in situ of the breast: an inter-institutional study

[1]  D. Oertli,et al.  Factors predicting in-breast tumor recurrence after breast-conserving surgery , 2009, Breast Cancer Research and Treatment.

[2]  T. Tot,et al.  Radiological–Pathological Correlation in Diagnosing Breast Carcinoma: The Role of Pathology in the Multimodality Era , 2008, Pathology & Oncology Research.

[3]  A. Marchetti,et al.  Fluorescent in situ hybridization as a screening test for HER2 amplification in G2 and G3 breast cancers of lobular and ductal histotype and metastases. , 2008, Oncology reports.

[4]  E. Rakovitch,et al.  Significance of multifocality in ductal carcinoma in situ: outcomes of women treated with breast-conserving therapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  J. Costantino,et al.  Pathologic variables predictive of breast events in patients with ductal carcinoma in situ. , 2007, American journal of clinical pathology.

[6]  K. Mokbel,et al.  Heterogeneity of ductal carcinoma in situ and its effects on management. , 2006, The Lancet. Oncology.

[7]  J. Peterse,et al.  Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853--a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.

[9]  L. Tabár,et al.  Mammographic–Pathologic Correlation of Ductal Carcinoma In Situ of the Breast Using Two- and Three-Dimensional Large Histologic Sections , 2005 .

[10]  Tibor Tot,et al.  DCIS, cytokeratins, and the theory of the sick lobe , 2005, Virchows Archiv.

[11]  G. Capitanio,et al.  Role of axillary sentinel lymph node biopsy in patients with pure ductal carcinoma in situ of the breast , 2005, BMC Cancer.

[12]  S. Swain,et al.  Ductal carcinoma in situ, complexities and challenges. , 2004, Journal of the National Cancer Institute.

[13]  M. Silverstein,et al.  Ductal carcinoma in situ: USC/Van Nuys Prognostic Index and the impact of margin status. , 2003, Breast.

[14]  J. Lara,et al.  The relevance of occult axillary micrometastasis in ductal carcinoma in situ , 2003, Cancer.

[15]  M. Silverstein.  The University of Southern California/Van Nuys prognostic index for ductal carcinoma in situ of the breast. , 2003, American journal of surgery.

[16]  C. Howe,et al.  Active signaling by HER-2/neu in a subpopulation of HER-2/neu-overexpressing ductal carcinoma in situ: clinicopathological correlates. , 2002, Cancer research.

[17]  K. Kerlikowske,et al.  Detection of ductal carcinoma in situ in women undergoing screening mammography. , 2002, Journal of the National Cancer Institute.

[18]  G. Cserni.  Sentinel Lymph Node Biopsy as a Tool for the Staging of Ductal Carcinoma In Situ in Patients with Breast Carcinoma , 2002, Surgery Today.

[19]  D. Schultz,et al.  Mammographically detected ductal carcinoma in situ of the breast treated with breast-conserving surgery and definitive breast irradiation: long-term outcome and prognostic significance of patient age and margin status. , 2001, International journal of radiation oncology, biology, physics.

[20]  L. Holmberg,et al.  Risk factors for subsequent invasive breast cancer and breast cancer death after ductal carcinoma in situ: a population-based case-control study in Sweden. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[21]  P. Rosen.  Rosen's Breast Pathology , 2001 .

[22]  L. Tabár,et al.  The Swedish Two-County Trial twenty years later. Updated mortality results and new insights from long-term follow-up. , 2000, Radiologic clinics of North America.

[23]  A. Patchefsky,et al.  Microinvasive breast carcinoma , 2000, Cancer.

[24]  J Costantino,et al.  Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight‐year update of Protocol B‐17 , 1999, Cancer.

[25]  James Dignam,et al.  Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial , 1999, The Lancet.

[26]  L. Holmberg,et al.  Ductal carcinoma in situ of the breast from a population-defined cohort: an evaluation of new histopathological classification systems. , 1999, European journal of cancer.

[27]  R. L. Bauer,et al.  Ductal carcinoma in situ-associated nipple discharge: A clinical marker for locally extensive disease , 1998, Annals of Surgical Oncology.

[28]  F. Tavassoli,et al.  Mammary ductal carcinoma in Situ with microinvasion , 1998, Cancer.

[29]  F. O'Malley,et al.  Relationship of a new histological categorization of ductal carcinoma in situ of the breast with size and the immunohistochemical expression of p53, c-erb B2, bcl-2, and ki-67. , 1997, Human pathology.

[30]  M. Lagios,et al.  Ductal carcinoma in situ of the breast: reproducibility of histological subtype analysis. , 1997, Human pathology.

[31]  M. Silverstein,et al.  A prognostic index for ductal carcinoma in situ of the breast , 1996, Cancer.

[32]  M. Lagios.  Heterogeneity of duct carcinoma in situ (DCIS): relationship of grade and subtype analysis to local recurrence and risk of invasive transformation. , 1995, Cancer letters.

[33]  B Fisher,et al.  Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. , 1993, The New England journal of medicine.

[34]  P. Validire,et al.  Paget's disease of the nipple without clinically and radiologically detectable breast tumor. Histochemical and immunohistochemical study of 44 cases. , 1993, Pathology, research and practice.

[35]  K. Zedeler,et al.  Lobular carcinoma in situ of the female breast. Short-term results of a prospective nationwide study. The Danish Breast Cancer Cooperative Group. , 1992, The American journal of surgical pathology.

[36]  K. Zedeler,et al.  Lobular Carcinoma In Situ of the Female Breast , 1992 .

[37]  C. Redmond,et al.  Breast tumor recurrence following lumpectomy with and without breast irradiation: an overview of recent NSABP findings. , 1992, Seminars in surgical oncology.

[38]  D. Morton,et al.  The impact of microinvasion on axillary node metastases and survival in patients with intraductal breast cancer. , 1990, Archives of surgery.

[39]  S. Feig,et al.  Heterogeneity of intraductai carcinoma of the breast , 1989 .

[40]  E. Mohamed,et al.  Ductal Carcinoma in situ of the female Breast , 2007 .

[41]  Peter Devilee,et al.  Pathology and Genetics of Tumours of the Breast and Female Genital Organs , 2003 .

[42]  D. Reintgen,et al.  Sentinel Node Biopsy in Ductal Carcinoma In Situ Patients , 2000, Annals of Surgical Oncology.

[43]  D. May,et al.  The National Breast and Cervical Cancer Early Detection Program: report on the first 4 years of mammography provided to medically underserved women. , 1998, AJR. American journal of roentgenology.

[44]  U. Chetty,et al.  Noninvasive ductal carcinoma of the breast: the relevance of histologic categorization. , 1993, Human pathology.